Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

PAVM

PAVmed Inc

Jan 02 • 04:00PM ET

7.33

+0.71 10.66 %

Healthcare • Medical Devices • USA • NASD

Peers: AVGR ICAD NUWE MLSS SINT BMTX RVP AXGN BLFS SMLR

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-12.00	Insider Own	31.70%	Shs Outstand	1.00M	Perf Week	-15.01%
Market Cap	7.30M	Forward P/E	-	EPS next Y	-17.10	Insider Trans	0.00%	Shs Float	0.75M	Perf Month	-25.78%
Enterprise Value	30.54M	PEG	-	EPS next Q	-4.50	Inst Own	68.30%	Short Float	1.91%	Perf Quarter	-44.49%
Income	-0.60M	P/S	251.66	EPS this Y	105.40%	Inst Trans	-	Short Ratio	0.75	Perf Half Y	-59.08%
Sales	0.03M	P/B	0.67	EPS next Y	-78.13%	ROA	9.00%	Short Interest	0.01M	Perf YTD	10.66%
Book/sh	11.00	P/C	2.15	EPS next 5Y	-	ROE	-	52W High	26.85 -72.70%	Perf Year	-61.91%
Cash/sh	3.41	P/FCF	-	EPS past 3/5Y	- 15.50%	ROIC	-	52W Low	6.30 16.35%	Perf 3Y	-95.46%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	81.61% -	Gross Margin	-	Volatility	17.44% 10.96%	Perf 5Y	-99.03%
Dividend TTM	-	EV/Sales	1053.04	EPS Y/Y TTM	-46.16%	Oper. Margin	-	ATR (14)	1.01	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.30	Sales Y/Y TTM	-99.28%	Profit Margin	-	RSI (14)	36.11	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.40	EPS Q/Q	-120.40%	SMA20	-19.71%	Beta	1.11	Target Price	315.00
Payout	0.00%	Debt/Eq	1.09	Sales Q/Q	-99.50%	SMA50	-29.28%	Rel Volume	2.41	Prev Close	6.62
Employees	39	LT Debt/Eq	0.21	Earnings	Nov 13 BMO	SMA200	-53.29%	Avg Volume	19.09K	Price	7.33
IPO	Apr 28, 2016	Option/Short	Yes / No	EPS/Sales Surpr.	-70.59% -60.00%	Trades		Volume	46,022	Change	10.66%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-30-21	Initiated	Cantor Fitzgerald	Overweight	$8
Nov-05-20	Initiated	Ascendiant Capital Markets	Buy	$5
Jun-28-18	Initiated	Maxim Group	Buy	$5

Dec-30-25 09:01AM	PAVmed Announces Reverse Stock Split (PR Newswire) -16.67%
Dec-09-25 08:01AM	Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection (PR Newswire) +6.17%
Nov-20-25 08:15AM	Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree (PR Newswire) -7.81%
Nov-13-25 04:02PM	PAVmed Inc (PAVM) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Financial ... (GuruFocus.com) -8.49% -9.53%
08:15AM	Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (PR Newswire)
08:00AM	Loading…
08:00AM	PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results (PR Newswire)
Nov-12-25 08:00AM	Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results (PR Newswire) +10.43%
07:39AM	PAVmed Inc (PAVM) Q3 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
Oct-30-25 08:01AM	PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025 (PR Newswire)
Oct-29-25 08:01AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025 (PR Newswire)
Oct-15-25 08:01AM	Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit (PR Newswire)
Oct-10-25 12:00PM	PAVmed (PAVM) Upgraded to Strong Buy: Here's Why (Zacks)
Oct-07-25 08:01AM	PAVmed Subsidiary, Veris Health and The Ohio State University Comprehensive Cancer Center Launch Commercial Phase of Strategic Partnership Agreement (PR Newswire) +7.98%
Sep-25-25 08:01AM	Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors (PR Newswire)
Sep-16-25 08:01AM	Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs (PR Newswire)
09:17AM	Loading…
Sep-11-25 09:17AM	Lucid Diagnostics Announces Closing of Public Offering of Common Stock (PR Newswire)
Sep-10-25 08:00AM	Lucid Diagnostics Announces Pricing of Public Offering of Common Stock (PR Newswire)
Sep-09-25 04:01PM	Lucid Diagnostics Announces Proposed Public Offering of Common Stock (PR Newswire)
Sep-05-25 09:16AM	Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025 (PR Newswire)
Aug-28-25 06:45AM	PAVmed plans to license Dukes oesophageal imaging technology (Medical Device Network)
Aug-27-25 08:00AM	Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025 (PR Newswire) -7.13%
Aug-26-25 08:01AM	PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology (PR Newswire) +6.16%
Aug-14-25 08:00AM	PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results (PR Newswire)
Aug-13-25 08:00AM	Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results (PR Newswire)
Aug-05-25 08:00AM	Lucid Diagnostics to Participate in Upcoming Investor Conferences (PR Newswire) -6.86%
Jul-31-25 08:01AM	PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025 (PR Newswire)
Jul-30-25 08:01AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025 (PR Newswire)
08:00AM	PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule (PR Newswire)
Jul-16-25 07:31AM	MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard Esophageal DNA Test (PR Newswire)
Jun-24-25 08:01AM	PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing (PR Newswire)
12:01PM	Loading…
Jun-18-25 12:01PM	Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test (PR Newswire)
Jun-04-25 08:41AM	PAVmed subsidiary Veris Health partners with Ohio State University cancer center (TipRanks)
Jun-03-25 08:31AM	PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (PR Newswire)
May-27-25 07:31AM	Lucid Diagnostics to Join Russell 2000 and Russell 3000 Indexes (PR Newswire)
May-15-25 08:01AM	PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results (PR Newswire) -13.72%
May-14-25 08:01AM	Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results (PR Newswire)
May-01-25 08:31AM	PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 (PR Newswire) +13.17%
Apr-30-25 08:31AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025 (PR Newswire)
Apr-28-25 12:00PM	PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know (Zacks) -5.26%
Apr-24-25 08:01AM	NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard Esophageal DNA Test in Patients Without Symptomatic GERD (PR Newswire)
Apr-11-25 09:23AM	Lucid Diagnostics Announces Closing of Public Offering of Common Stock (PR Newswire)
Apr-09-25 07:24PM	Lucid Diagnostics Announces Pricing of Public Offering of Common Stock (PR Newswire) +15.21%
04:01PM	Lucid Diagnostics Announces Proposed Public Offering of Common Stock (PR Newswire)
Apr-03-25 09:00AM	Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-27-25 08:01AM	Lucid Diagnostics Launches 'Embrace the Future' Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology (PR Newswire) -5.77%
Mar-25-25 11:08AM	PAVmed Inc. (PAVM) Q4 2024 Earnings Call Transcript (SeekingAlpha) -5.06%
08:01AM	PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Mar-24-25 08:01AM	Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Mar-20-25 08:31AM	Lucid Diagnostics Announces Updated National Comprehensive Cancer Network (NCCN) Guidelines Now Include Esophageal Precancer Screening (PR Newswire)
Mar-18-25 08:31AM	Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard Esophageal Precancer Testing Accepted for Peer-Reviewed Publication (PR Newswire)
Mar-13-25 07:36AM	Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard Esophageal DNA Test (PR Newswire)
Mar-11-25 09:01AM	PAVmed to Hold a Business Update Conference Call and Webcast on March 25, 2025 (PR Newswire)
Mar-10-25 09:01AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025 (PR Newswire)
Mar-05-25 04:45PM	Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering (PR Newswire)
Mar-04-25 08:25AM	Lucid Diagnostics Announces $15.3 Million Registered Direct Offering (PR Newswire)
Feb-27-25 08:31AM	Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard in At-Risk Patients without Symptomatic GERD (PR Newswire) +10.00%
Feb-25-25 08:31AM	Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Feb-24-25 08:31AM	PAVmed and Subsidiary Veris Health Complete Private Placement Financing (PR Newswire)
Feb-20-25 08:31AM	Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health (PR Newswire)
Feb-18-25 08:30AM	PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement (PR Newswire) +6.08%
Feb-06-25 08:57AM	Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (PR Newswire)
Jan-13-25 07:56AM	Lucid Diagnostics Announces Record Quarterly EsoGuard Test Volume (PR Newswire)
Dec-23-24 08:01AM	Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule (PR Newswire) +10.82%
Dec-19-24 08:01AM	Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters (PR Newswire)
Dec-11-24 08:01AM	Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard Esophageal DNA Test Accepted for Peer-Reviewed Publication (PR Newswire)
Dec-03-24 08:01AM	Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones (PR Newswire) +6.31%
Nov-20-24 07:56AM	Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard Esophageal DNA Test (PR Newswire)
Nov-18-24 08:15AM	Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (PR Newswire) -10.53%
Nov-14-24 08:01AM	PAVmed Provides Business Update and Third Quarter 2024 Financial Results (PR Newswire) +6.86%
Nov-13-24 08:01AM	Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results (PR Newswire) -8.93%
Nov-07-24 08:01AM	Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing Accepted for Peer-Reviewed Publication (PR Newswire)
Nov-05-24 08:01AM	Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers (PR Newswire)
Oct-31-24 08:31AM	PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 (PR Newswire)
Oct-30-24 08:31AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024 (PR Newswire)
Oct-15-24 07:51AM	Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test (PR Newswire) -8.18%
Oct-10-24 07:51AM	PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care (PR Newswire) -6.40%
Oct-09-24 08:01AM	Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit (PR Newswire)
Oct-08-24 07:49AM	Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024 (PR Newswire)
Oct-01-24 08:01AM	Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players (PR Newswire) +8.13%
Sep-24-24 08:01AM	American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test (PR Newswire)
Sep-16-24 04:30PM	PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements (PR Newswire)
Sep-10-24 07:56AM	Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress (PR Newswire) +43.70%
Sep-03-24 07:51AM	Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health (PR Newswire) +30.42%
Aug-20-24 08:16AM	Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard for Early Detection of Esophageal Precancer and Cancer (PR Newswire)
Aug-13-24 08:16AM	The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard to Enhance Early Detection of Esophageal Cancer (PR Newswire) -7.50%
08:01AM	PAVmed Provides Business Update and Second Quarter 2024 Financial Results (PR Newswire)
Aug-12-24 08:07AM	Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results (PR Newswire)
Aug-08-24 08:31AM	Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard #CheckYourFoodTube Precancer Testing Event (PR Newswire)
Aug-06-24 08:15AM	Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard Esophageal Precancer Testing (PR Newswire)
Aug-05-24 08:15AM	Lucid Diagnostics to Participate in Upcoming Investor Conferences (PR Newswire)
Jul-30-24 08:15AM	PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024 (PR Newswire) -15.84%
Jul-29-24 08:15AM	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024 (PR Newswire)
Jul-23-24 08:01AM	Lucid Diagnostics Announces Record Quarterly EsoGuard Test Volume (PR Newswire)
Jul-11-24 08:31AM	Lucid Diagnostics Launches New Corporate Website (PR Newswire)
Jul-02-24 07:55AM	Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing in a Screening Population (PR Newswire) -7.07%
Jun-13-24 07:58AM	PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (PR Newswire) +5.71%
Jun-12-24 08:05AM	4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard Esophageal Precancer Testing (PR Newswire) -9.48%
May-14-24 08:21AM	Lucid Diagnostics Inc. (NASDAQ:LUCD) Q1 2024 Earnings Call Transcript (Insider Monkey) +15.62%
07:53AM	PAVM Stock Earnings: PAVmed Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
May-13-24 08:43PM	PAVmed Provides Business Update and First Quarter 2024 Financial Results (PR Newswire) -9.43%

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PAVM

PAVmed Inc

Upgrade your FINVIZ experience